- Home
- DTST vs COCH Comparison
DTST vs COCH Comparison
Compare DTST & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTST | COCH |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 51.0M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DTST | COCH |
|---|---|---|
| Price | $3.02 | $0.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.4K | ★ 97.0K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3671.43 | 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,382,929.00 | $241,000.00 |
| Revenue This Year | $25.39 | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $2.85 | $0.36 |
| 52 Week High | $5.15 | $1.89 |
Technical Indicators
Market Signals| Indicator | DTST | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 57.47 |
| Support Level | $2.92 | $0.63 |
| Resistance Level | $3.67 | $0.77 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 15.73 | 46.86 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.